Open AccessPrevalence and Factors Associated With Statin Use Among a Nationally Representative Sample of US Adults: National Health and Nutrition Examination Survey, 2011–2012
Author(s) -
Adedinsewo Demilade,
Taka Nchang,
Agasthi Pradyumna,
Sachdeva Rajesh,
Rust George,
Onwuanyi Anekwe
Publication year - 2016
Publication title -
clinical cardiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.263
H-Index - 72
eISSN - 1932-8737
pISSN - 0160-9289
DOI - 10.1002/clc.22577
Subject(s) - medicine , national health and nutrition examination survey , statin , dyslipidemia , diabetes mellitus , confidence interval , odds ratio , logistic regression , demography , gerontology , disease , environmental health , population , endocrinology , sociology
The 2013 American College of Cardiology/American Heart Association guidelines recommend statins for adults age ≤75 years who have clinical atherosclerotic cardiovascular disease ( IA ) and adults age 40 to 75 years with diabetes mellitus and LDL‐C 70–189 mg/dl ( IA ). Our aim was to estimate the prevalence and likelihood of statin use among selected statin benefit groups. Using data from the National Health and Nutrition Examination Survey ( NHANES ) 2011–2012, we examined 5319 adults age ≥20 years. We estimated weighted frequencies and prevalence of statin use for adults with diabetes mellitus and dyslipidemia (or low‐density lipoprotein cholesterol ≥70 mg/ dL ), defined as statin benefit group 1 ( SBG1 ); and for adults with atherosclerotic cardiovascular disease, defined as statin benefit group 2 ( SBG2 ). We constructed a logistic regression model to estimate odds of statin use in SBG1 . Overall, an estimated 38.6 million Americans are on a statin. In adjusted models, uninsured and Hispanic adults were less likely to be on a statin compared with white adults; 59.5% (95% confidence interval [ CI ]: 53.0‐66.1) of all adults in SBG1 , 58.8% (95% CI : 51.5‐66.1) of adults age 40 to 75 in SBG1 , and 63.5% (95% CI : 55.6‐71.4) of all adults in SBG2 were on a statin. Although the prevalence of statin use has increased over time, Hispanic ethnicity and lack of insurance remain barriers to statin use. Black‐white racial disparities were not significant. Our study provides a baseline estimate of statin use in the noninstitutionalized population just prior to introduction of the new guidelines and provides a reference for evaluating the impact of the new guidelines on statin utilization.